COMPANY

Senti Biosciences

HQ: South San Francisco, CA source · sentibio.com ↗ · West Coast

Keywords: gene therapy oncology solid tumors cell therapy synthetic biology solid tumor AML/MDS CD33 Expressing Hematological Malignancies FLT3 Expressing Hematological Malignancies inflammatory bowel disease SENTI-202

Profile checked Oct 10, 2026

$37.6MRaised (2 yrs)1Trials (company is sponsor)2NIH grants

Funding and NIH signals

SEC Form D raise Raised $10M in debt securities (Form D filed Jun 4, 2026). SEC Form D 0001193125-26-256064 (Jun 4, 2026)
Evidence (1 event)
- Jun 4, 2026 · SEC Form D 0001193125-26-256064
  Name of Issuer: Senti Biosciences Holdings, Inc.; CIK: 1854270; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-04; Industry Group: Biotechnology; Date of First Sale: 2026-05-20; Types of Securities Offered: Debt, Other (Guarantee); Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 10000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Dec 2, 2024 Raise Private placement: $37.6M (total, as published), announced Dec 2, 2024. Source: SEC filing. source ↗
Apr 22, 2024 Trial start Phase 1: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS source ↗

Funding

Raised: $37.6M. Last 2 years.

Dec 2, 2024 Private placement: $37.6M (total, as published), announced Dec 2, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06325748	SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS	Phase 1	Active, not recruiting	Apr 22, 2024	2026-02 (estimated)

NIH awards 2

Annual award amounts. Total $2.2M.

2021 NIH contract (government contract; not a grant and not an investment round) 75N91021C00026-0-9999-1 FY2021: $1,999,993 awarded for that fiscal year; activity N44 (OTHER_NIH); PI LEE, GARY; recipient as written: SENTI BIOSCIENCES, INC., SOUTH SAN FRANCISCO, CA. source ↗
Sep 18, 2018 NIH award 1R43DK117752-01A1 FY2018: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI LEE, PHILIP; recipient as written: SENTI BIOSCIENCES, INC., SOUTH SAN FRANCISCO, CA. Engineering Cell Therapies to Tr source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-06-04 Raise Private raise (SEC Form D): $10.0M sold of $40.0M offered; issuer “Senti Biosciences Holdings, Inc.”. Verified from the SEC filing. SEC filing ↗
2024-12-19 Raise Private raise (SEC Form D): $37.6M sold of $120.6M offered; issuer “Senti Biosciences, Inc.”. Verified from the SEC filing. SEC filing ↗